The Irish arm of US engineering and construction company Jacobs Engineering increased profits by more than a quarter in the year ended 30 September 2025, according to the Irish Times, driven by increased activity across the pharmaceutical, biotechnology, transportation and water sectors in which its clients operate.

Accounts for the period show the company generated a profit of €14.8 million, up from €11.6 million the previous year. Turnover was down 2.5% to €437.4 million, while cost of sales fell 8% from €377.5 million to €348 million, resulting in improved margins. The company held net current assets of €71.4 million at year end, with no dividend declared.

The profit improvement was attributed to a rise in professional services revenue alongside a reduction in pass-through revenues, which relate primarily to procurement and subcontractor elements of significant projects and typically carry lower margins than professional services work.

Jacobs Engineering Ireland added 23 people over the period, bringing its headcount to 628. Staff costs rose to €67 million from €62.6 million, while administrative expenses increased by 23%, driven by cost inflation and higher headcount.

The company, which designs and builds plants for the pharmaceutical, biotech and energy industries and counts Pfizer and Intel among its Irish clients, described its order backlog as "very healthy." It said it is working on nine new business opportunities each worth at least €2 million in revenue, with a greater than 35% probability of winning each.

The company said new contracts planned for the first two quarters of the new year "may bring over 500,000 of additional billable hours," adding that "the board is confident that 2026 will be a strong year, as we are well positioned to gain market share in all sectors and expand our customer base."

Jacobs said geopolitical events have not had a material impact on the business but flagged supply chain challenges and building cost inflation as risks facing both the company and its clients across Irish and international markets.